Business Context and Reporting Period
This Form 8-K, filed on May 23, 2023, by Angion Biomedica Corp. (Angion), provides supplemental disclosures regarding its proposed merger with Elicio Therapeutics, Inc. (Elicio). The filing updates the proxy statement/prospectus/information statement previously filed in connection with the Merger Agreement entered into on January 17, 2023. The document addresses legal challenges, corrections to financial projections, and executive compensation arrangements.
Key Financial Metrics and Valuation
The filing does not report historical revenue, profit, or cash flow for Angion or Elicio for a specific reporting period. Instead, it details corrections to Elicio's unaudited financial projections used in valuation analyses:
- Valuation Correction: Due to mathematical errors in calculating unlevered free cash flows (incorrectly adding interest income to EBIT and reversing working capital adjustments), the implied total equity value of Elicio was revised downward. The range decreased from $561 million–$773 million to $402 million–$573 million.
- Ownership Impact: Following the correction, the calculated range of Angion's equity value as a percentage of the combined company increased from 6.1%–8.2% to 8.0%–11.1%.
- Angion Cash Position: The filing references a projection that Angion would have less than $30 million in cash by the end of 2023. Elicio's net cash as of December 31, 2022, was estimated at $7.8 million.
- Executive Compensation: A Retention Bonus Plan was adopted for CEO Dr. Jay Venkatesan and EVP Jennifer Rhodes, providing bonuses equal to 100% of base salary ($608,000 and $440,840, respectively) upon a change in control, plus additional lump-sum payments upon qualifying termination.
Material Changes and Corrections
The primary material change disclosed is the identification of errors in the financial projections for Elicio:
- Calculation Errors: Interest income was inadvertently added to EBIT, and working capital changes were reversed (increases deducted instead of added, and vice versa).
- Revenue Omission: Grant revenue was inadvertently omitted from the disclosure of estimated total global revenue for 2023 in the original proxy statement.
- Revised Projections: Corrected projections show Total Global Revenue of $2 million for 2023 and Unlevered Free Cash Flow of $(12) million for 2023.
- Board Reconfirmation: Despite the valuation adjustments, the Angion Board unanimously reconfirmed that the Merger remains advisable and fair to stockholders.
Legal Proceedings, Risks, and Outlook
Legal Proceedings:
- Klein Complaint: A lawsuit filed on February 17, 2023, challenging the Merger was voluntarily dismissed by the plaintiff on February 21, 2023.
- Stockholder Demands: Between February 23 and May 18, 2023, Angion received eight demands from stockholders alleging material omissions or misrepresentations in the Registration Statement. Additionally, a books and records demand was received on April 19, 2023.
- Company Stance: Angion and its Board deny the allegations but are providing supplemental disclosures to avoid litigation disruption.
Risks and Contingencies:
- Additional lawsuits or demands may be filed, or the dismissed Klein Complaint may be refiled.
- The Merger is subject to stockholder approval and satisfaction of closing conditions.
- Forward-looking statements regarding the Merger's completion and effects involve significant uncertainties.
Investor Verification Checklist
- Verify the corrected financial projections for Elicio, specifically the revised Unlevered Free Cash Flow and Total Global Revenue figures for 2023–2039.
- Confirm the updated implied equity value range for Elicio ($402 million–$573 million) and the corresponding impact on Angion's ownership percentage in the combined entity.
- Review the status of the eight stockholder demands and the books and records request to assess potential litigation risks.
- Examine the terms of the Retention Bonus Plan for Dr. Venkatesan and Ms. Rhodes, including the specific payout triggers and amounts.
- Ensure the proxy statement/prospectus/information statement has been updated to reflect the corrected data and legal disclosures.